June 30, 2025 7:26am

Record highs, June jobs report, tax cuts, murky inflation data, possibilities of interest and tariff rates coming to a head as cell and gene therapy sector’s fair value feels the pain

The sword will fall just depends on when ...

News: Moderna (MRNA +$1.59 and trending pre-open) flu vaccine shows positive late-stage P3 trial results, paving way for combination Covid shot. MRNA’s experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for MRNA to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.

The last session of June is today and then markets will close at 1 p.m. on Thursday and remain shut on Friday for the 4th of July.

Pre-open Indications:  2 Sell into Strength, 2 Negative and 2 Positive

Never leave an investor uninformed …

I say what others won’t, so you can do what others can’t!

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

“I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Friday’s night’s … RegMed Investors (RMi) Closing Bell: Econ’s inflation data was hotter than expected as May PCE pushes rate cuts odds lower … https://www.regmedinvestors.com/articles/13978

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): PONZI Scheme at its best or was convicted Bernie Madoff also resurrected … https://www.regmedinvestors.com/articles/13812

 

Monday: The pre-open Dow futures are UP +0.54% or (+239 points), the S&P futures are UP +0.44% or (+27 points) and the Nasdaq futures are UP +0.62% or (+141 points)

  • Stock futures rose early Monday 6/30/25 as investors look to cap June,
  • European stocks mixed as UK-U.S. trade deal cuts autos, aviation tariffs,
  • Asia-Pacific markets trade mixed as investors parse a slew of data releases

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

  • Friday: The Dow closed UP +432.43 points or +1%, the S&P closed UP +32.05 points or +0.52% while the Nasdaq closed UP +105.54 points or +0.52%
  • Thursday: The Dow closed UP +404.41 points or +0.94%, the S&P closed UP +48.86 points or +0.80% while the Nasdaq closed UP +194.36 points or +0.97%
  • Wednesday: The Dow closed DOWN -160.59 points or -0.25%, the S&P closed DOWN -0.02 points or -0.00% while the Nasdaq closed UP +61.02 points or +0.31%
  • Tuesday: The Dow closed UP +507.24 points or +1.19%, the S&P closed UP +67.01 points or +1.11% while the Nasdaq closed UP +281.56 points or +1.43%
  • Monday: The Dow closed UP +374.96 points or +0.89%, the S&P closed UP +57.35 points or +0.96% while the Nasdaq closed UP +183.57 points or +0.94%
  • Last week: The S&P 500 rose +3.5%, the Dow added +3.8% while the Nasdaq popped +4.1%

Economic Data Docket: MNI Chicago PMI, June (42.7 expected, 40.5 prior); Dallas Fed manufacturing activity       

 

Q2 – June – 1 market holiday, 1 neutral, 8 negative, and 10 positive closes

  • May – 1 market holiday, 10 negative and 11 positive closes
  • Q2 - April – 10 negative and 11 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.  A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

  • Yet again, I am passing on forecasting the daily indications due to the effects of PCE onto expectation … it is still a mix of ups, downs and just uncertainty

Although:

  • Ultragenyx Pharmaceuticals (RARE) closed down -$0.60 after Thursday’s -$0.31 and Wednesday’s +$0.27 with a negative -$0.38 or -1.04% after market
  • Adverum Biotechnologies (ADVM) closed down -$0.17 after Thursday’s -$0.09 and Wednesday’s +$0.0 with a negative -$0.05 or -2.16% aftermarket
  • Solid Biosciences (SLDB) closed down -$0.09 after Thursday’s +$0.07, Wednesday’s -$0.115, Tuesday’s +$0.34 and Monday’s -$0.28 with a positive +$0.10 or +2.199% aftermarket
  • Moderna (MRNA) closed down -$0.38 after Thursday’s +$0.68, Wednesday’s +$0.06, Tuesday’s +$1.13 and Monday’s -$0.26 with a positive trending on news in pre-open 
  • Mesoblast (MESO) closed up +$0.17 after Thursday’s +$0.20 and Wednesday’s +$0.10 with a neutral aftermarket – SELL into Strength
  • AxoGen (AXGN) +$0.03 after Thursday’s +$0.22, Wednesday’s +$0.11, Tuesday’s +$0.36 and Monday’s +$0.06 with a positive +$0.10 or +0.29$ aftermarket – SELL into Strength

 

The BOTTOM LINE: July on the way and summer doldrums …

  • More pressure to come into the economy [and that will lead to] income and share price erosion and a consumer spending slowdown. That is really the picture that we should expect in the 2H/25

Final session of June …?

Last and final full week <6/23 to 6/27> 1st session, Monday closed negative followed by Tuesday’s positive close to today’s Wednesday’s and Thursday’s negative close as uncertainty slows to month’s end <Monday, 6/30>.

Signs of cooling in the labor market have been a key part of the brewing debate over Fed policy and will put further emphasis on the incoming June jobs report, due out for release at 8:30 a.m. ET on Thursday.

  • Economists expect the report to show 116,00 nonfarm payrolls were added, a move lower from the 139,000 seen in May. The unemployment rate is anticipated to have moved up to 4.3% from 4.2% the month prior.

 

Interesting Info this month of June: The M&A list evolves: Blueprint Medicine (BPMC) by Bristol Meyers (BMY), Sage Therapeutics by Supernus Pharmaceuticals (SUPN), CureVac (CVAC) by BioNTech (BNTX) and now Verve Therapeutics (VERV) by Eli Lilly (LLY)

 

June ’25: understand the “flow” of markets, the cell and gene therapy sector and economic karma…

Last week:

  • 6/27 – Friday closed negative with 10 positive, 21 negative and 4 flats
  • 6/26 - Thursday closed negative with 14 positive, 18 negative and 3 flats
  • 6/25 - Wednesday closed negative with 14 positive, 17 negative and 4 flats
  • 6/24 - Tuesday closed positive with 30 positive, 3 negative and 2 flats
  • 6/23 - Monday closed negative with 15 positive, 16 negative and 4 flats

The previous week:

  • 6/20 - Friday closed negative with 14 positive, 18 negative and 3 flats
  • 5/19 – Thursday was a market holiday
  • 6/18 – Wednesday closed positive with 21 positive, 11 negative and 3 flats
  • 6/17 - Tuesday closed negative with 10 positive, 23 negative and 2 flats
  • 6/16 - Monday closed positive with 20 positive, 11 negative and 4 flats

 

Reiterating, “There are always some big ifs, especially given some of the headlines that could emanate after a past few months of news flatulence.

  • Some believe in a “June Swoon;” however, June will be no better or worse than any other month. Although, I consider the so-called summer rally after the peripatetic or wandering.”

As always, brace ourself for more volatility, economics and their down trending affect?

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed.